Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02856477
NCT02856477TerminatedNot Applicable

Pharmacogenetic in the Therapeutic Strategy in Depressed Elderly

Centre Hospitalier Universitaire de Besancon2 sites in 1 country28 target enrollmentStarted: November 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
28
Locations
2
Primary Endpoint
patient remission
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients.

Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
70 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •current major depressive disorder
  • •antidepressant treatment

Exclusion Criteria

  • •dextromethorphan contra-indication
  • •other psychiatric disorder
  • •kidney failure
  • •liver failure mini mental State Examination (MMSE)<18

Outcomes

Primary Outcomes

patient remission

Time Frame: 6 months

remission is defined by a Montgomery and asberg depression rating (MADRS) score\<10.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
Pharmacogenetic-Directed Treatment for Major DepressionDepression
NCT01261364Assurex Health Inc.50
Completed
Not Applicable
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of DepressionBipolarMood DisorderDepression
NCT02189057Mayo Clinic160
Unknown
Not Applicable
Predict Antidepressant Responsiveness Using PharmacogenomicsDepressive SymptomsDepression
NCT01228357Samsung Medical Center1,000
Unknown
Phase 4
Pharmacogenomics Studies of AntidepressantsAntidepressive AgentsPharmacogeneticsVenlafaxineFluoxetineMajor Depressive Disorder
NCT01204086National Cheng-Kung University Hospital200
Completed
Not Applicable
Clinical Pharmacogenomics of Antidepressant ResponseDepression
NCT00384020National Health Research Institutes, Taiwan402